These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 34227789)

  • 1. Favipiravir Induced Nephrotoxicity in Two Patients of COVID-19.
    Nasa P; Shrivastava P; Kulkarni A; Vijayan L; Singh A
    J Assoc Physicians India; 2021 Jan; 69(1):90. PubMed ID: 34227789
    [No Abstract]   [Full Text] [Related]  

  • 2. Favipiravir Induced Nephrotoxicity in two Patients of COVID-19.
    Nasa P; Shrivastava PK; Kulkarni A; Vijayan L; Singh A
    J Assoc Physicians India; 2021 Jun; 69(6):11-12. PubMed ID: 34472793
    [No Abstract]   [Full Text] [Related]  

  • 3. Comment on: Favipiravir, an antiviral for COVID-19?
    Chachaima-Mar J; Pérez-Castilla J
    J Antimicrob Chemother; 2021 Jan; 76(1):279-280. PubMed ID: 32888000
    [No Abstract]   [Full Text] [Related]  

  • 4. A Favipiravir-induced Fever in a Patient with COVID-19.
    Kurita T; Ishida K; Muranaka E; Sasazawa H; Mito H; Yano Y; Hase R
    Intern Med; 2020; 59(22):2951-2953. PubMed ID: 33191372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Favipiravir as an Antiviral Agent in Coronavirus Disease 2019 (COVID-19): Same Script, Different Cast?
    Dauby N
    Clin Infect Dis; 2021 Aug; 73(3):e847-e848. PubMed ID: 33075124
    [No Abstract]   [Full Text] [Related]  

  • 6. Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19).
    McCullough PA
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32967849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance: a case series.
    Fu D; Cao R; Zhao L; Li W; Zhong W; Wen J
    Crit Care; 2020 Sep; 24(1):578. PubMed ID: 32977854
    [No Abstract]   [Full Text] [Related]  

  • 8. Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019.
    Hase R; Kurata R; Ishida K; Kurita T; Muranaka E; Mito H
    Intern Med; 2020 Sep; 59(18):2327-2329. PubMed ID: 32727996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case studies of SARS-CoV-2 treated with favipiravir among patients in critical or severe condition.
    Takahashi H; Iwasaki Y; Watanabe T; Ichinose N; Okada Y; Oiwa A; Kobayashi T; Moriya M; Oda T
    Int J Infect Dis; 2020 Nov; 100():283-285. PubMed ID: 32829044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Favipiravir-induced fever in coronavirus disease 2019: A report of two cases.
    Takoi H; Togashi Y; Fujimori D; Kaizuka H; Otsuki S; Wada T; Takeuchi Y; Abe S
    Int J Infect Dis; 2020 Dec; 101():188-190. PubMed ID: 32992014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An unusual case of bluish discoloration of the cornea after favipiravir therapy for COVID-19.
    Raiturcar TP; Nayak CA
    Indian J Ophthalmol; 2021 Dec; 69(12):3778-3779. PubMed ID: 34827050
    [No Abstract]   [Full Text] [Related]  

  • 12. Virological and genomic analysis of SARS-CoV-2 from a favipiravir clinical trial cohort.
    Suzuki M; Imai T; Sakurai A; Komoto S; Ide T; Lim CK; Shintani A; Doi Y; Murata T
    J Infect Chemother; 2021 Sep; 27(9):1350-1356. PubMed ID: 34176716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of early-stage combination treatment with favipiravir and methylprednisolone for severe COVID-19 pneumonia: A report of 11 cases.
    Murohashi K; Hagiwara E; Kitayama T; Yamaya T; Higa K; Sato Y; Otoshi R; Shintani R; Okabayashi H; Ikeda S; Niwa T; Nakazawa A; Oda T; Okuda R; Sekine A; Kitamura H; Baba T; Komatsu S; Iwasawa T; Kaneko T; Ogura T
    Respir Investig; 2020 Nov; 58(6):430-434. PubMed ID: 32893160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Favipiravir versus standard of care in patients with severe COVID-19 infections: A retrospective comparative study.
    Almoosa Z; Saad M; Qara S; Mustafa M; Mansour A; Alshab D; Alhashem J; ALKhawajah S; Alkhalifah S; ALmarzooq M; ALzain M; Anshasi N; Ahmed G; Mutair AA
    J Infect Public Health; 2021 Sep; 14(9):1247-1253. PubMed ID: 34464921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluorescence of ocular surface in a Covid -19 patient after Favipiravir treatment: a case report.
    Doran MA; Aytogan H; Ayıntap E
    Virol J; 2021 Jul; 18(1):146. PubMed ID: 34256791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two Cases of Severe COVID-19 Pneumonia Effectively Treated with Extracorporeal Membrane Oxygenation in Addition to Favipiravir and Corticosteroid.
    Shinoda M; Kamachi K; Ota S; Yoshimatsu L; Boku R; Yoshida Y; Hirouchi T; Shinada K; Sato T; Morikawa M; Iwata K; Matsumoto T; Shinkai M
    Intern Med; 2021; 60(1):123-130. PubMed ID: 33390469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-2.
    Pertinez H; Rajoli RKR; Khoo SH; Owen A
    J Antimicrob Chemother; 2021 Jul; 76(8):2121-2128. PubMed ID: 34075418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug Fever Due to Favipiravir Administration for the Treatment of a COVID-19 Patient.
    Tawara J; Uehara T; Sakao S; Igari H; Taniguchi T; Kasai H; Takayanagi S; Yahaba M; Shimada R; Ikusaka M
    Intern Med; 2021 Apr; 60(7):1115-1117. PubMed ID: 33583886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A possible interaction between favipiravir and methotrexate: Drug-induced hepatotoxicity in a patient with osteosarcoma.
    Demir E; Sütcüoğlu O; Demir B; Ünsal O; Yazıcı O
    J Oncol Pharm Pract; 2022 Mar; 28(2):445-448. PubMed ID: 34255596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Favipiravir for treating patients with novel coronavirus (COVID-19): protocol for a systematic review and meta-analysis of randomised clinical trials.
    Arab-Zozani M; Hassanipour S; Ghoddoosi-Nejad D
    BMJ Open; 2020 Jul; 10(7):e039730. PubMed ID: 32737100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.